Biotie Therapies Oyj : Biotie: Selincro launched in the United Kingdom

    Biotie Therapies Oyj : Biotie: Selincro launched in the United Kingdom


Biotie: Selincro launched in the United Kingdom

Biotie today announced that its partner H.Lundbeck A/S (Lundbeck) has launched
Selincro in the United Kingdom. According to the terms of the license
agreement between Biotie and Lundbeck for Selincro, Biotie is eligible fora
milestone payment of EUR 2 million related to the UK launch. Biotie will
potentially contribute to Lundbeck towards any required post approval
commitment studies. These contributions are not expected to be significant in

Lundbeck will continue the rollout of Selincro in additional European markets
through 2013 and into 2014.

Turku, 6 May 2013

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

Timo Veromaa President and CEO
tel. +358 2274 8900, email:

Virve Nurmi, Investor Relations Manager
tel. +358 2 274 8900, e-mail:

NASDAQ OMX Helsinki Ltd

Main Media

ABOUT SELINCRO (nalmefene):

Selincro is indicated for the reduction of alcohol consumption in adult
patients with alcohol dependence who have a high drinking risk level (>60
g/day for men, >40 g/day for women) without physical withdrawal symptoms and
who do not require immediate detoxification. Selincro should be prescribed in
conjunction with continuous psychosocial support focused on treatment
adherence and the reduction of alcohol consumption. Treatment should be
initiated only in patients who continue to have a high drinking risk level two
weeks after an initial assessment. Selincro is to be taken as-needed; that is,
on each day the patient perceives a risk of drinking alcohol, one tablet
should be taken, preferably 1-2 hours prior to the anticipated time of

Biotie has licensed global rights to Selincro to Lundbeck. Under the terms of
the agreement, Biotie is eligible for up to EUR 89 million in upfront and
milestone payments plus royalties on sales of Selincro. Upon payment of the UK
launch milestone, Biotie will have received EUR 14 million of such milestone
payments from Lundbeck. Further payments of up to EUR 2 million are expected
on commercial launch of Selincro in each of France, Germany, Italy and Spain,
and further potential milestone payments on launches in certain other markets
and if the product reaches certain predetermined sales. Lundbeck is
responsible for the registration, manufacturing and marketing of the product.


Biotie is a specialized drug development company focused on the development of
drugs for neurodegenerative and psychiatric disorders (e.g. Parkinson's
disease, Alzheimer's disease and other cognitive disorders, alcohol and drug
dependence (addiction) and post-traumatic stress disorder), and inflammatory
and fibrotic liver disease. The company has a strong and balanced development
portfolio with several innovative small molecule and biological drug
candidates at different stages of clinical development. Biotie's products
address diseases with high unmet medical need and significant market

Biotie's most advanced product, Selincro (nalmefene), licensed to H. Lundbeck
A/S, has on 28 February 2013 received European marketing authorization for the
reduction of alcohol consumption in adult patients with alcohol dependence who
have a high level of alcohol consumption. In addition, Biotie has a strategic
collaboration with UCB Pharma S.A. covering tozadenant which is transitioning
into Phase 3 development for Parkinson's disease. Biotie shares are listed on
NASDAQ OMX Helsinki Ltd.


This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: Biotie Therapies Oyj via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.